Zepp Health Q4 revenue rose 43% to USD 85.2 million as net loss narrowed 70.2% to USD 11 million

Reuters09:00

<a href="https://laohu8.com/S/ZEPP">Zepp Health</a> Q4 revenue rose 43% to USD 85.2 million as net loss narrowed 70.2% to USD 11 million

Zepp Health published an unaudited earnings release covering fourth-quarter and full-year 2025 results. Q4 revenue rose 43% to USD 85.2 million, and gross margin expanded 3.6 percentage points to 40.4% on a more favorable product mix and pricing power during promotional periods. Q4 net loss attributable to shareholders narrowed 70.2% to USD 11 million, while cash and cash equivalents plus restricted cash totaled USD 112.9 million. For FY2025, revenue increased 41.8% to USD 258.9 million and net loss attributable to shareholders narrowed 47.1% to USD 40.1 million. For Q1 2026, Zepp forecast net revenues of USD 50 million to USD 55 million, implying 30% to 43% growth, and said the quarter benefited from strong Amazfit sales during Black Friday and Christmas and new product launches including Amazfit Active Max and Amazfit T-Rex Ultra 2.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zepp Health Corporation published the original content used to generate this news brief via PR Newswire (Ref. ID: 202603152100PR_NEWS_USPR_____CN10348) on March 16, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2619284484?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-16 09:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2619284484","market":"fut","top_or_hot":-1,"title":"Zepp Health Q4 revenue rose 43% to USD 85.2 million as net loss narrowed 70.2% to USD 11 million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/ZEPP\">Zepp Health</a> Q4 revenue rose 43% to USD 85.2 million as net loss narrowed 70.2% to USD 11 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Zepp Health published an unaudited earnings release covering fourth-quarter and full-year 2025 results. Q4 revenue rose 43% to USD 85.2 million, and gross margin expanded 3.6 percentage points to 40.4% on a more favorable product mix and pricing power during promotional periods. Q4 net loss attributable to shareholders narrowed 70.2% to USD 11 million, while cash and cash equivalents plus restricted cash totaled USD 112.9 million. For FY2025, revenue increased 41.8% to USD 258.9 million and net loss attributable to shareholders narrowed 47.1% to USD 40.1 million. For Q1 2026, Zepp forecast net revenues of USD 50 million to USD 55 million, implying 30% to 43% growth, and said the quarter benefited from strong Amazfit sales during Black Friday and Christmas and new product launches including Amazfit Active Max and Amazfit T-Rex Ultra 2.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zepp Health Corporation published the original content used to generate this news brief via PR Newswire (Ref. ID: 202603152100PR_NEWS_USPR_____CN10348) on March 16, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Zepp Health Q4 revenue rose 43% to USD 85.2 million as net loss narrowed 70.2% to USD 11 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nZepp Health Q4 revenue rose 43% to USD 85.2 million as net loss narrowed 70.2% to USD 11 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-16 09:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/ZEPP\">Zepp Health</a> Q4 revenue rose 43% to USD 85.2 million as net loss narrowed 70.2% to USD 11 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Zepp Health published an unaudited earnings release covering fourth-quarter and full-year 2025 results. Q4 revenue rose 43% to USD 85.2 million, and gross margin expanded 3.6 percentage points to 40.4% on a more favorable product mix and pricing power during promotional periods. Q4 net loss attributable to shareholders narrowed 70.2% to USD 11 million, while cash and cash equivalents plus restricted cash totaled USD 112.9 million. For FY2025, revenue increased 41.8% to USD 258.9 million and net loss attributable to shareholders narrowed 47.1% to USD 40.1 million. For Q1 2026, Zepp forecast net revenues of USD 50 million to USD 55 million, implying 30% to 43% growth, and said the quarter benefited from strong Amazfit sales during Black Friday and Christmas and new product launches including Amazfit Active Max and Amazfit T-Rex Ultra 2.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zepp Health Corporation published the original content used to generate this news brief via PR Newswire (Ref. ID: 202603152100PR_NEWS_USPR_____CN10348) on March 16, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ZEPP","symbol_name":"华米科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nNDL9yHX8L:1","article_id":"2619284484","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2619284484","pubTimestamp":1773622842,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Zepp Health published an unaudited earnings release covering fourth-quarter and full-year 2025 results. Q4 revenue rose 43% to USD 85.2 million, and gross margin expanded 3.6 percentage points to 40.4% on a more favorable product mix and pricing power during promotional periods. Q4 net loss attributable to shareholders narrowed 70.2% to USD 11 million, while cash and cash equivalents plus restricted cash totaled USD 112.9 million. For FY2025, revenue increased 41.8% to USD 258.9 million and net loss attributable to shareholders narrowed 47.1% to USD 40.1 million. For Q1 2026, Zepp forecast net revenues of USD 50 million to USD 55 million, implying 30% to 43% growth, and said the quarter benefited from strong Amazfit sales during Black Friday and Christmas and new product launches including Amazfit Active Max and Amazfit T-Rex Ultra 2.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ZEPP":"华米科技","BK4157":"电子设备和仪器","LU0274383008.USD":"MANULIFE GF ASIAN SMALL CAP EQUITY \"AA\" (USD) INC"},"translate_title":"Zepp Health第四季度收入增长43%至8520万美元，净亏损收窄70.2%至1100万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ZEPP":0.9},"content_text":"Zepp Health Q4 revenue rose 43% to USD 85.2 million as net loss narrowed 70.2% to USD 11 million\n    \n\n        Zepp Health published an unaudited earnings release covering fourth-quarter and full-year 2025 results. Q4 revenue rose 43% to USD 85.2 million, and gross margin expanded 3.6 percentage points to 40.4% on a more favorable product mix and pricing power during promotional periods. Q4 net loss attributable to shareholders narrowed 70.2% to USD 11 million, while cash and cash equivalents plus restricted cash totaled USD 112.9 million. For FY2025, revenue increased 41.8% to USD 258.9 million and net loss attributable to shareholders narrowed 47.1% to USD 40.1 million. For Q1 2026, Zepp forecast net revenues of USD 50 million to USD 55 million, implying 30% to 43% growth, and said the quarter benefited from strong Amazfit sales during Black Friday and Christmas and new product launches including Amazfit Active Max and Amazfit T-Rex Ultra 2.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zepp Health Corporation published the original content used to generate this news brief via PR Newswire (Ref. ID: 202603152100PR_NEWS_USPR_____CN10348) on March 16, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2619284484","isCrawlerRequest":true}